Reform steps pay out – S&P upgrades rating of Greece to BB-

On Friday S&P upgraded the sovereign rating of Greece to BB-. The outlook remains positive. The rating agency cites in particular the reduced budgetary risks, the removal of all capital controls, the improved economic outlook, and the advantageous debt profile of Greece.

Highlights:

  • On Friday S&P upgraded the sovereign rating of Greece to BB-. The outlook remains positive.
  • The rating agency cites in particular the reduced budgetary risks, the removal of all capital controls, the improved economic outlook, and the advantageous debt profile of Greece.
  • We share S&P’s overall positive assessment. The growth rate is expected to remain well above the euro area average and the new (conservative) government remains committed to fulfill its fiscal targets and to go ahead with economic reforms.
  • Greek government bonds have been by far the best performing euro area government bond market year-to-date. Given the very low yield environment and speculations that Greek sovereign bonds will eventually be included in the ECB’s QE programme, we see leeway for a furter moderate spread tightening.

Download the full publication below

REFORM STEPS PAY
OUT – S&P UPGRADES
RATING
OF GREECE TO BB-

RELATED INSIGHTS

CHINA’S RECOVERY CONTINUED BUT A BIT SOFTER THAN EXPECTED
China's economic recovery continued in Q3 2020, although a bit softer than expected. Real GDP growth rose to 4.9% yoy, slightly below the Reuters consensus expectation of 5.2% yoy, but still a substantial upturn from the 3.2% yoy in Q2. On a quarterly base, growth dynamics softened to 2.7% qoq, after 11.7% qoq and -10% qoq in the two previous quarters.
Citywire video-interview with Peter Marber
Watch Peter Marber, fund manager of this global, non-directional, long/short approach to Emerging Markets debt, in a video-interview by Citywire.
COVID-19 FACTS & FIGURES
According to the IMF’s Managing Director, strong international cooperation on coronavirus vaccine could speed up the world economic recovery and add $9 trillion to global income by 2025. A WHO trial found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon have little or no effect on hospitalized Covid-19 patients. Gilead Sciences has questioned the findings of the WHO study saying data appeared inconsistent.